James Wysock, MD, MS, presented “Role of Whole Gland Ablation in Prostate Cancer” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Wysock, James. “Role of Whole Gland Ablation in Prostate Cancer.” October, 2024. Accessed Nov 2025. https://grandroundsinurology.com/role-of-whole-gland-ablation-in-prostate-cancer/
Role of Whole Gland Ablation in Prostate Cancer – Summary
James Wysock, MD, MS, delves into the evolving role of whole gland ablation (WGA) in prostate cancer management, particularly in intermediate- to high-risk cases and challenging clinical scenarios.
In this 20-minute presentation, Dr. Wysock highlights specific patient profiles where WGA may be preferable, including those with prior pelvic radiation, contraindications to surgery or radiotherapy, or elderly patients seeking less invasive yet effective treatment. In the salvage setting, WGA offers a compelling alternative for local recurrences, achieving substantial cancer control while avoiding aggressive surgical or radiation options.
Technological advancements like TULSA and HIFU enhance WGA precision. Challenges such as recurrence rates and in-field failures underscore the need for meticulous treatment planning and expanded ablation margins.
Dr. Wysock advocates for trials to validate WGA as a mainstream option, particularly in patients who cannot undergo radical treatments. This approach aligns with evolving guidelines and patient preferences, underscoring WGA’s potential as a transformative option in prostate cancer care.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
James S. Wysock, MD, MSc, is a Clinical Assistant Professor of Urology at New York University Grossman School of Medicine in New York, New York. Dr. Wysock also serves as the Division Chief of Urology at Bellevue Hospital Center in New York City. His research focuses on advanced imaging techniques and treatment tools to optimize cancer diagnostics and therapy. Dr. Wysock’s clinical research efforts focus on image-guided prostate cancer diagnosis and treatment, including MRI-US fusion biopsy and partial gland prostate ablation techniques, and his specialization in urologic oncology includes cancers of the kidneys, bladder, ureters, testes, and prostate.
